The estimated Net Worth of Ali Behbahani is at least $275 Milion dollars as of 17 July 2023. Ali Behbahani owns over 333,333 units of Oyster Point Pharma Inc stock worth over $273,344,019 and over the last 10 years he sold OYST stock worth over $1,220,183. In addition, he makes $377,917 as Chairman of the Board at Oyster Point Pharma Inc.
Sign up
Ali Behbahani OYST stock SEC Form 4 insiders trading
Ali has made over 20 trades of the Oyster Point Pharma Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he bought 333,333 units of OYST stock worth $999,999 on 17 July 2023.
The largest trade he's ever made was buying 12,000,000 units of Oyster Point Pharma Inc stock on 7 September 2018 worth over $20,040,000. On average, Ali trades about 789,252 units every 20 days since 2014. As of 17 July 2023 he still owns at least 24,471,264 units of Oyster Point Pharma Inc stock.
You can see the complete history of Ali Behbahani stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Ali Behbahani biography
Dr. Ali Behbahani M.D. serves as Chairman of the Board of the Company. Dr. Behbahani joined New Enterprise Associates (NEA) in 2007 and is currently a general partner on the healthcare team. Prior to joining NEA, he worked as an intern and later as a consultant in business development at The Medicines Company, a specialty pharmaceutical company developing acute care cardiovascular products. He previously held positions as a Venture Associate at Morgan Stanley Venture Partners from 2000 to 2002 and as a Healthcare Investment Banking Analyst at Lehman Brothers from 1998 to 2000. He has been a member of the board of directors of Genocea Biosciences (Nasdaq:GNCA) since February 2018, CRISPR Therapeutics (Nasdaq:CRSP) since April 2015, and Adaptimmune Therapeutics (Nasdaq:ADAP) since September 2014, Black Diamond Therapeutics, Inc. (Nasdaq:BDTX) since December 2018 and was on the board of Nevro Corp. (NYSE:NVRO) from August 2014 to March 2019. Dr. Behbahani received a B.S. in biomedical engineering, electrical engineering and chemistry from Duke University, an M.B.A. from the Wharton School of the University of Pennsylvania and an M.D. from the University of Pennsylvania School of Medicine. Behbahani is qualified to serve on our Board due to his experience in the biopharmaceutical industry and his experience as a member of the boards of directors of multiple companies in the industry.
What is the salary of Ali Behbahani?
As the Chairman of the Board of Oyster Point Pharma Inc, the total compensation of Ali Behbahani at Oyster Point Pharma Inc is $377,917. There are 7 executives at Oyster Point Pharma Inc getting paid more, with Jeffrey Nau having the highest compensation of $4,037,700.
How old is Ali Behbahani?
Ali Behbahani is 43, he's been the Chairman of the Board of Oyster Point Pharma Inc since 2020. There are 5 older and 1 younger executives at Oyster Point Pharma Inc. The oldest executive at Oyster Point Pharma Inc is William Link, 74, who is the Independent Director.
What's Ali Behbahani's mailing address?
Ali's mailing address filed with the SEC is 2855 SAND HILL ROAD, , MENLO PARK, CA, 94025.
Insiders trading at Oyster Point Pharma Inc
Over the last 5 years, insiders at Oyster Point Pharma Inc have traded over $24,486,000 worth of Oyster Point Pharma Inc stock and bought 3,552,871 units worth $59,028,668 . The most active insiders traders include Ali Behbahani, Venture Capital Vi, L.P.Ver... oraz Clare Ozawa. On average, Oyster Point Pharma Inc executives and independent directors trade stock every 27 days with the average trade being worth of $2,204,444. The most recent stock trade was executed by Daniel Lochner on 1 November 2021, trading 8,590 units of OYST stock currently worth $98,871.
What does Oyster Point Pharma Inc do?
Oyster Point Pharma is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases. Oyster Point Pharma's lead product candidate, OC-01 (varenicline) nasal spray, a highly selective cholinergic agonist, is being developed as a nasal spray to treat the signs and symptoms of dry eye disease. In pre-clinical and clinical studies, OC-01 (varenicline) nasal spray was shown to have a novel mechanism of action via activation of the trigeminal parasympathetic pathway to stimulate the glands and cells responsible for natural tear film production, known as the lacrimal functional unit.
What does Oyster Point Pharma Inc's logo look like?
Complete history of Ali Behbahani stock trades at Adaptimmune Therapeutics Plc, CRISPR Therapeutics AG, Genocea Biosciences Inc, Regulus Therapeutics Inc, Savara Inc, Nevro Corp, Mirum Pharmaceuticals Inc, Oyster Point Pharma Inc, Black Diamond Therapeutics Inc, Trevi Therapeutics, Marker Therapeutics, Akouos, Nkarta, Metacrine oraz Bright Health
Oyster Point Pharma Inc executives and stock owners
Oyster Point Pharma Inc executives and other stock owners filed with the SEC include:
-
Jeffrey Nau,
President, Chief Executive Officer, Director -
John Snisarenko,
Chief Commercial Officer -
Daniel Lochner,
Chief Financial Officer -
Dr. Jeffrey Nau Ph.D., MMS,
Pres, CEO & Director -
Daniel Lochner M.B.A.,
Chief Financial Officer -
John Snisarenko M.B.A.,
Chief Commercial Officer -
Mark Murray,
Director -
Ali Behbahani,
Chairman of the Board -
Benjamin Tsai,
Independent Director -
Aimee Weisner,
Independent Director -
William Link,
Independent Director -
Clare Ozawa,
Independent Director -
Tim McCarthy,
IR Contact Officer -
Michael Atieh,
Director -
Dr. Marian Macsai M.D.,
Chief Medical Officer of Medical Affairs -
Loni Da Silva M.S.,
Sr. VP of Regulatory Affairs -
Raegan A. McClain CCEP, J.D., L.L.M.,
Chief Compliance Officer -
Barry Rosenfeld J.D.,
Sr. VP & Gen. Counsel -
Dr. Eric Carlson Ph.D.,
Chief Scientific Officer -
George Donato M.B.A.,
Sr. VP of CMC & Operations -
Ventures, Llc Vida,
10% owner -
Point Pharma I, Llc Oyster,
10% owner -
Vision Llckkr Healthcare St...,
-
Gp Iv, L.L.C.Inv Opps Iv, L...,
-
Michael Ackermann,
Director -
Perkins Caufield & Byers Xi...,
-
Venture Capital Vi, L.P.Ver...,
-
Fund Holdings L.P.Kravis He...,
-
George Christopher Eliades,
Director -
Donald J Santel,
Director -
Enterprise Associates 14, L...,